Maternal Thyroid Care Before and During Pregnancy

Thyroid function has a direct bearing on fertility, placental development, fetal growth and the health of the pregnant person. Pregnancy changes iodine needs, thyroid hormone production and the interpretation of laboratory results, so a result that appears acceptable outside pregnancy may need closer attention during gestation.

For families in Australia, care often involves a GP, midwife, obstetrician, endocrinologist or fertility specialist, with testing arranged through Medicare-funded services where eligible. The practical approach is to identify people at higher risk, use pregnancy-appropriate reference ranges and adjust treatment promptly while avoiding unnecessary medication or investigations.

Why Thyroid Hormones Matter In Pregnancy

Thyroid hormones support early brain and nervous system development, especially before the fetal thyroid becomes fully functional. They also help regulate maternal energy use, cardiovascular function and the processes that allow the placenta to develop normally. Untreated overt hypothyroidism has been associated with miscarriage, hypertensive disorders, anaemia, preterm birth and impaired fetal development.

Hyperthyroidism can create different risks, including palpitations, weight loss, heat intolerance, poor weight gain, pre-eclampsia, fetal growth restriction and, rarely, thyroid storm. Graves’ disease requires particular care because thyroid-stimulating antibodies can cross the placenta even when the mother’s current thyroid hormone levels are controlled.

Symptoms alone are not reliable. Tiredness, constipation, anxiety, sweating and changes in weight may be attributed to normal pregnancy, while a mild thyroid disorder can produce few obvious signs. A blood test is therefore more useful than symptom-based reassurance when risk factors are present.

Who Should Be Offered Thyroid Testing

There is ongoing international debate about universal screening of every pregnant person compared with targeted case finding. In Australian practice, many clinicians arrange thyroid function tests for people with a personal or family history of thyroid disease, goitre, autoimmune conditions, type 1 diabetes, infertility, recurrent miscarriage or previous pregnancy complications. Prior thyroid surgery, radioactive iodine treatment or use of thyroid medication also warrants early review.

Testing is particularly important when there are signs of thyroid dysfunction, a known thyroid nodule or a history of Graves’ disease. People taking levothyroxine should generally have their treatment reviewed as soon as pregnancy is confirmed rather than waiting for the first routine antenatal appointment. A GP in suburban Melbourne, a community clinic in Cairns and a regional service in western New South Wales may follow different referral pathways, but the need for timely thyroid function testing is the same.

A typical initial panel includes thyroid-stimulating hormone, or TSH, and free thyroxine, or FT4. Thyroid peroxidase antibodies may help assess autoimmune thyroiditis, while TSH-receptor antibodies are important for current or previous Graves’ disease. Results should be interpreted with trimester-specific ranges and awareness of the laboratory’s assay, because pregnancy alters the usual relationship between TSH and FT4.

Managing Hypothyroidism And Borderline Results

Established hypothyroidism is treated with levothyroxine, a synthetic form of thyroxine that is considered safe in pregnancy. People already taking it often need a dose increase early in gestation, although the adjustment should be guided by the treating clinician and laboratory results. Levothyroxine is best taken consistently with water, separated from iron, calcium and some antacids, which can reduce absorption.

Overt hypothyroidism generally requires treatment without delay. Subclinical hypothyroidism, where TSH is elevated but FT4 remains within range, calls for a more individual assessment. The decision may depend on the TSH level, thyroid antibody status, gestational age, symptoms and local specialist guidance. TPO antibody positivity can increase the likelihood of progression and may influence the threshold for treatment.

Monitoring is usually repeated around every four to six weeks during the first half of pregnancy and after significant dose changes. The goal is to maintain thyroid hormone availability within the pregnancy-specific target rather than simply chase a normal non-pregnant TSH. Once stable, testing intervals may lengthen, but thyroid function still needs review later in pregnancy and after birth.

Treating Hyperthyroidism Safely

The most common cause of true hyperthyroidism in pregnancy is Graves’ disease. Treatment aims to control maternal symptoms and prevent complications while using the lowest effective antithyroid drug dose. Excessive treatment can cause fetal hypothyroidism and goitre, so both maternal blood tests and fetal wellbeing matter.

Propylthiouracil is often preferred during the first trimester because methimazole and carbimazole have been linked with a small risk of specific birth defects when used early in pregnancy. After the first trimester, clinicians may consider changing therapy because propylthiouracil carries a rare but serious risk of liver injury. These medicines must never be swapped or stopped without medical advice.

Some people develop temporary thyrotoxicosis from high human chorionic gonadotropin levels, particularly with severe nausea, vomiting or multiple pregnancy. This can settle as pregnancy progresses and may not require antithyroid medication. Radioactive iodine is contraindicated during pregnancy and breastfeeding. Surgery is reserved for selected cases, such as medication intolerance or uncontrolled disease, and is generally safest in the second trimester.

A history of Graves’ disease deserves specialist planning even after thyroid ablation or surgery. TSH-receptor antibodies can remain elevated, and ultrasound monitoring may be arranged if levels suggest fetal risk. Fetal tachycardia, growth restriction, goitre or excess amniotic fluid can indicate thyroid stimulation and require coordinated obstetric and endocrine care.

Iodine, Diet And Medication Timing

Iodine is needed to make thyroid hormones, and requirements rise during pregnancy and breastfeeding. Australian antenatal guidance commonly supports a daily iodine supplement containing 150 micrograms during pregnancy and breastfeeding, unless a clinician advises otherwise. A prenatal vitamin may already contain iodine, so checking the label prevents accidental duplication.

Seafood, dairy products, eggs and iodised salt contribute iodine, although dietary patterns vary. Kelp and seaweed products can contain highly unpredictable iodine amounts and may provide too much. People with thyroid disease should discuss supplements with their GP, pharmacist or endocrinologist rather than assuming that a “natural” product is harmless.

Iron and calcium are frequently prescribed in pregnancy and can interfere with levothyroxine absorption. A practical routine might involve levothyroxine on waking and prenatal vitamins with food later in the day, with the exact interval confirmed by the prescriber. This simple medication-timing issue is a common reason for apparently unstable TSH results.

Coordinating Antenatal And Newborn Care

Thyroid disease should be included in the shared antenatal record so that the GP, midwife, obstetric team and endocrinologist can see current medication and test results. In Australia, access to an endocrinologist can be slower outside Sydney, Brisbane, Perth or Adelaide, making early referral and clear communication particularly valuable. Telehealth can help regional families, although blood tests and fetal assessments still need local arrangements.

Placental function and fetal growth are assessed according to the overall clinical picture. Thyroid disease may sit alongside diabetes, hypertension or autoimmune illness, and those conditions can alter the monitoring plan. When placental concerns arise, placental pathology findings can sometimes help clinicians understand growth restriction, inflammation or vascular problems after birth, although pathology is not a substitute for antenatal thyroid management.

People from Aboriginal and Torres Strait Islander communities, families experiencing housing or transport insecurity, and those travelling long distances for care may need flexible appointment planning. A written medication plan, pathology request and direct contact pathway can reduce missed reviews. Interpreters and culturally safe services are essential when language, trust or previous healthcare experiences affect access.

Preparing For Birth And The Postpartum Period

Well-controlled thyroid disease does not usually determine the mode or timing of birth. The birth team should know about current antithyroid medication, recent thyroid results and any history of thyroid-receptor antibodies. Babies exposed to maternal Graves’ antibodies may need observation and blood tests after birth, even when the mother has had thyroid surgery or radioactive iodine in the past.

Levothyroxine requirements often change after delivery, commonly returning towards the pre-pregnancy dose, but the correct adjustment depends on the individual plan. Thyroid function is usually checked postpartum, particularly if symptoms develop or the dose was increased during pregnancy. Breastfeeding is compatible with levothyroxine and, in many cases, with carefully selected antithyroid therapy at prescribed doses.

Postpartum thyroiditis can cause a short period of anxiety, tremor, sweating or a racing heart, followed by fatigue, low mood, constipation and cold intolerance. These symptoms can be mistaken for sleep deprivation or normal adjustment to a newborn. Repeat testing helps distinguish postpartum thyroiditis from recurrent Graves’ disease or ordinary exhaustion.

The wider perinatal record can also include other maternal infections and fetal investigations. For example, discussions about maternal HIV prevention illustrate why pregnancy care works best when medication, laboratory testing, birth planning and newborn follow-up are considered together rather than handled as isolated issues.

When Specialist Review Is Needed

Urgent medical assessment is appropriate for severe breathlessness, chest pain, fainting, persistent rapid heartbeat, confusion, high fever or uncontrolled vomiting. These symptoms can have many causes, but serious thyroid complications must be excluded. A thyroid storm is uncommon but life-threatening, while severe hypothyroidism can also impair maternal and fetal wellbeing.

Specialist input is advisable for markedly abnormal TSH or FT4, suspected Graves’ disease, high TSH-receptor antibodies, thyroid nodules, previous thyroid cancer, difficult medication absorption or repeated dose instability. It is also useful when fertility treatment is planned, because optimising thyroid status before conception can reduce avoidable delays and complications.

Fetal imaging is not routinely required for uncomplicated thyroid disease. If a separate concern about fetal anatomy, growth or placental structure appears, the appropriate test depends on the clinical question. In selected cases, fetal MRI guidance may complement ultrasound, but it does not replace thyroid blood tests or standard antenatal surveillance.

The safest pathway is proactive rather than reactive: review thyroid history before conception where possible, test promptly after pregnancy is confirmed when risk is present, take medication consistently and repeat blood tests at the intervals advised. Australian families can ask their GP or maternity service to document the target range, dose, next pathology date and referral contact in the antenatal record, making care easier to follow from the first trimester through the postnatal check.